AstraZeneca PLC Net Income 2011-2026 | AZN

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income AstraZeneca PLC

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	115 M	3.2 B	1.34 B	2.16 B	3 B	3.5 B	2.82 B	1.23 B	2.56 B	6.3 B	9.98 B

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
9.98 B	115 M	3.29 B

Quarterly Net Income AstraZeneca PLC

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	550 M	-	-	-	738 M	-	-	-	107 M	-	-	-	319 M	-	-	-	446 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
738 M	107 M	432 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	-4.27 M	$ 0.79	-1.15 %	$ 4.31 M	China
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
AbCellera Biologics ABCL	-146 M	$ 3.49	0.58 %	$ 1.04 B	Canada
Frequency Therapeutics FREQ	-117 M	-	-	$ 528 M	USA
argenx SE ARGX	-408 M	$ 700.45	-1.19 %	$ 25 B	Niderland
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Alterity Therapeutics Limited ATHE	-12.8 M	$ 3.6	1.41 %	$ 8.66 B	Australia
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Grifols, S.A. GRFS	265 M	$ 7.81	-2.01 %	$ 6.83 B	Spain
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	-384 M	$ 225.98	-1.32 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	-230 M	$ 4.13	-5.06 %	$ 105 M	Schweiz
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
Allena Pharmaceuticals ALNA	-48.7 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-62.9 M	-	10.36 %	$ 9.8 M	USA
BioCardia BCDA	-11.6 M	$ 1.26	-0.79 %	$ 26.7 M	USA
AlloVir ALVR	-58.8 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Anika Therapeutics ANIK	-82.7 M	$ 14.2	-0.7 %	$ 208 M	USA
Aptose Biosciences APTO	-25.4 M	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
Athersys ATHX	-87 M	-	3.77 %	$ 22.4 M	USA
BioNTech SE BNTX	10.3 B	$ 91.19	1.21 %	$ 27.2 B	Germany
Aptinyx APTX	-64.8 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	-11.7 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-221 M	$ 1.44	-1.37 %	$ 367 M	Britain
Arcturus Therapeutics Holdings ARCT	-65.8 M	$ 6.68	-4.57 %	$ 183 M	Israel
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
AVEO Pharmaceuticals AVEO	-53.3 M	-	-	$ 521 M	USA
Burford Capital Limited BUR	172 M	$ 7.92	1.67 %	$ 1.31 B	Britain
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-13.6 M	$ 2.54	-5.22 %	$ 16 M	USA
Certara CERT	-1.6 M	$ 6.67	1.6 %	$ 1.07 B	USA
Athira Pharma ATHA	-96.9 M	-	-	$ 269 M	USA
Can-Fite BioPharma Ltd. CANF	-7.88 M	$ 3.6	-4.0 %	$ 7.83 B	Israel
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aravive ARAV	-76.3 M	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	-11.6 M	-	-2.5 %	$ 5.88 M	USA